MedTrace Logo

HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study

NCT05167071 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2025-04-27

No results posted yet for this study

Summary

To select RP2D/MTD of HBM4003 in combination with Toripalimab in dose confirmation part(Part 1) and use the RP2D in dose expansion part (Part 2) to evaluate the safety, tolerability, PK/PD and preliminary efficacy of in patients with advanced NEN and other solid tumors

Conditions

Interventions

DRUG

HBM4003

Subjects will be treated with HBM4003 on Day 1 during each 21-day cycle.

DRUG

Toripalimab

Subjects will be treated with Toripalimab on Day 1 during each 21-day cycle.

DRUG

Tislelizumab

Subjects will be treated with Tislelizumab on Day 1 during each 21-day cycle.

Sponsors & Collaborators

  • Harbour BioMed (Guangzhou) Co. Ltd.

    lead INDUSTRY

Principal Investigators

  • Lin Shen, Ph.D · Peking University Cancer Hospital & Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-28
Primary Completion
2025-09-30
Completion
2026-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05167071 on ClinicalTrials.gov